News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Policy
Novartis AG Says FDA Wants New Galvus Study; Shares Drop
February 26, 2007
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
ZURICH, Feb 26 (Reuters) - U.S. regulators are unlikely to request a long-term clinical study on Novartis AG's diabetes drug Galvus, the company said on Monday.
>>>
Discuss This Story
Twitter
LinkedIn
Facebook
Email
Print
Regulatory
Europe
MORE ON THIS TOPIC
Vaccines
FDA Plans Black Box Warning for COVID-19 Vaccines: Report
December 12, 2025
·
3 min read
·
Heather McKenzie
Approvals
First Commissioner’s Priority Review Approval Goes to Decades-Old Antibiotic
December 10, 2025
·
2 min read
·
Tristan Manalac
Podcast
Weight Loss Waves, Pazdur’s Exit and FDA Instability, New Neuro Breakthroughs
December 10, 2025
·
1 min read
·
Heather McKenzie
Regulatory
Regeneron Climbs Back After a Year of Regulatory, Manufacturing Misery
December 10, 2025
·
3 min read
·
Annalee Armstrong
